The Sound of Evolution
Frovatriptan
Mechanism of action:
Frovatriptan is a selective serotonin 5-HT₁B/5-HT₁D receptor agonist. Frovatriptan activates 5-HT₁B receptors on intracranial vascular smooth muscle, causing constriction of meningeal and intracranial blood vessels and reducing vascular pain signaling. It also activates 5-HT₁D receptors located on trigeminal nerve endings, inhibiting the release of pro-inflammatory and pain-related neuropeptides such as substance P and neurokinin A, thereby reducing neurogenic inflammation and pain transmission.
Reference(s):
1. Markus F et al. (2007). Frovatriptan review. Expert Opin Pharmacother.
2. Easthope SE et al. (2001). Frovatriptan. CNS Drugs.
3. Balbisi EA et al. (2006). Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag.